Skip to Content

Generic Rapivab Availability

Rapivab is a brand name of peramivir, approved by the FDA in the following formulation(s):

RAPIVAB (peramivir - solution;intravenous)

  • Manufacturer: BIOCRYST
    Approval date: December 19, 2014
    Strength(s): 200MG/20ML (10MG/ML) [RLD]

Has a generic version of Rapivab been approved?

No. There is currently no therapeutically equivalent version of Rapivab available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapivab. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Cyclopentane and cyclopentene compounds and use for detecting influenza virus
    Patent 6,503,745
    Issued: January 7, 2003
    Inventor(s): Pooran; Chand & Yarlagadda S.; Babu & Shanta; Bantia
    Assignee(s): Biocryst Pharmaceuticals, Inc.

    New cyclopentane and cyclopentene compounds are provided along with their use in method for detecting influenza virus.

    Patent expiration dates:

    • November 5, 2019
      Drug substance
  • Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
    Patent 6,562,861
    Issued: May 13, 2003
    Inventor(s): Yarlagadda S.; Babu & Pooran; Chand & John A.; Montgomery
    Assignee(s): BioCryst Pharmaceuticals, Inc.

    Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1′S)-(−)-(1′-acetylamino-2 ′-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<

    Patent expiration dates:

    • December 17, 2018
      Drug substance
  • Antiviral treatments
    Patent 8,778,997
    Issued: July 15, 2014
    Assignee(s): BioCryst Pharmaceuticals, Inc.

    The invention provides unit dosage forms, kits, and methods useful for treating viral infections.

    Patent expiration dates:

    • May 7, 2027

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 19, 2019 - NEW CHEMICAL ENTITY
    • September 20, 2020 - NEW PATIENT POPULATION

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.